Clinical trials: Blood Pressure, High
Renal Disorder
Antiproteinuric Efficacy of Losartan Potassium in Patients With Non-Diabetic Proteinuric Renal Diseases (0954-213)
Antiproteinuric Efficacy of Losartan Potassium in Patients with Non-Diabetic Proteinuric Renal Diseases.
- Trial name
- NCT00140985
- Testing
- MK0954, losartan potassium/Duration of Treatment: 20 weeks, Comparator: amlodipine / Duration of Treatment: 20 weeks
- Volunteers
- 97 people
- Sponsor
- Organon and Co
Pulmonary Arterial Hypertension (PAH)
A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag
This study will look at safety and tolerability of LIQ861 (treprostinil) inhalation powder in adults with pulmonary arterial hypertension (PAH, WHO Group 1) who switch from selexipag, a medicine taken by mouth, to treprostinil, a…
- Trial name
- NCT07759804
- Testing
- LIQ861 (treprostinil) inhalation powder
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Liquidia Technologies, Inc.
Glaucoma
Multi-Arm Feasibility Study Evaluating OTX-TP Compared to Timolol in Treatment of Subjects With Open Angle Glaucoma
The purpose of this study is to evaluate how OTX-TP, a sustained release travoprost drug product, when placed in the canaliculus of the eyelid compares to timolol drops for the lowering of intraocular pressure (IOP) in patients…
- Trial name
- NCT01845038
- Testing
- OTX-TPa ~4µg/day over 2 mos. with natural tears drops, OTX-TPb ~3µg/day over 3 months with natural tears drops, Timolol Maleate (0.5%) dosed twice daily with punctum plug without drug
- Where
- South Africa
- Volunteers
- 41 people
- Sponsor
- Ocular Therapeutix, Inc.
Pulmonary Arterial Hypertension
Evaluate The Clinical Effectiveness, Safety And Tolerability Of Sildenafil Used In Doses ≥20mg TID For The Treatment Of Pulmonary Arterial Hypertension
The objective of this observational study is to gain clinical insight on the actual use of sildenafil citrate (Revatio™) for the treatment of pulmonary arterial hypertension (PAH).
- Trial name
- NCT01365585
- Testing
- sildenafil citrate
- Where
- 2 sites in Germany, Ireland
- Volunteers
- 227 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Type 2 Diabetes Mellitus, Hypertension
Dose-ranging Study to Evaluate the Effectiveness and Tolerability of MK0736 in Patients With Type 2 Diabetes Mellitus (T2DM) and Hypertension (0736-007)
The study will assess the efficacy and tolerability of MK0736 in patients with Type 2 Diabetes Mellitus and Hypertension who are on ongoing therapy with Angiotensin-Converting Enzyme or Angiotensin Receptor Blocker.
- Trial name
- NCT00806585
- Testing
- MK-0736, Comparator: HCTZ
- Volunteers
- 620 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Arterial Hypertension
Safety and Efficacy of BIA 5-1058 in PAH
This study aims to assess the safety and tolerability of the individual highest tolerated zamicastat doses, achieved in the study BIA-51058-201, during long-term treatment in Pulmonary Arterial Hypertension (PAH) disease.
- Trial name
- NCT06009185
- Testing
- Oral zamicastat
- Where
- 11 sites in Austria, Germany and 4 more
- Volunteers
- 20 people
- Sponsor
- Bial - Portela C S.A.
Hypertension
Natriuretic Effect of Telmisartan Versus Placebo in Patients With Mild-to-Moderate Hypertension
Study to compare the natriuretic effect of telmisartan to placebo in mild-to-moderate hypertensive patients on a controlled sodium diet as well as to explore the effects of telmisartan on norepinephrine, plasma renin activity…
- Trial name
- NCT02176499
- Testing
- Telmisartan, low dose, Telmisartan, high dose
- Volunteers
- 26 people
- Sponsor
- Boehringer Ingelheim
Glaucoma, Ocular Hypertension
Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®
Comparing Safety and Efficacy of Combigan® and Lumigan® with Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated with Xalatan®.
- Trial name
- NCT01170884
- Testing
- fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution, bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Allergan
Open Angle Glaucoma, Ocular Hypertension
Three Month Safety and Efficacy Study of TRAVATAN® Versus Travoprost Ophthalmic Solution, 0.004%
A multi-center, observer-masked, randomized, parallel group efficacy and safety study of TRAVATAN® versus a new formulation of Travoprost Ophthalmic Solution, 0.004%
- Trial name
- NCT01452009
- Testing
- Travoprost Ophthalmic Solution, 0.004% (New Formulation), TRAVATAN®
- Sponsor
- Alcon Research
Hypertension
ConfidenHT System for Diagnostic Electrical Mapping of Renal Nerves
To evaluate the safety and performance of the ConfidenHT System
- Trial name
- RDN (NCT02777216)
- Testing
- ConfidenHT system
- Where
- 3 sites in Greece, Netherlands
- Volunteers
- 20 people
- Sponsor
- BlueWind Medical
Pulmonary Arterial Hypertension
Pharmacokinetics, Safety and Tolerability of Concurrent Doses of BIA 5-1058 and Furosemide
The purpose of this study is: To assess the effect of BIA 5 1058 400 mg on furosemide pharmacokinetics (PK). To assess the effect of furosemide 40 mg on the PK of BIA 5 1058.
- Trial name
- NCT07173738
- Testing
- BIA 5-1058, Furosemide, BIA 5-1058 and Furosemide
- Where
- United Kingdom
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Hypertension, Left Ventricular Hypertrophy
Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension
Left ventricular hypertrophy (LVH) increases the risk of cardiovascular morbidity and mortality in patients with high blood pressure, compared to those without LVH.
- Trial name
- NCT00139555
- Testing
- amlodipine/benazepril
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Novartis
Pulmonary Arterial Hypertension
Efficacy and Safety Study of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH)
This is a placebo-controlled, double-blind, phase II clinical study to evaluate the efficacy and safety of Udenafil in patient with Pulmonary Arterial Hypertension(PAH).
- Trial name
- NCT01553721
- Testing
- udenafil
- Where
- 9 sites in South Korea
- Volunteers
- 63 people
- Sponsor
- Dong-A ST Co., Ltd.
Essential Hypertension
A Multicenter, Randomized, Double-Blind Phase 3 Trial of KDF1901 in Patients With Essential Hypertension
This randomized, double-blind, multicenter phase 3 clinical trial evaluated the efficacy and safety of KDF1901, a single-pill triple combination of valsartan, amlodipine, and chlorthalidone, in patients with essential…
- Trial name
- NCT07116863
- Testing
- KDF1901-R0, KDF1901-L, KDF1901
- Where
- 2 sites in South Korea
- Volunteers
- 286 people
- Sponsor
- Kyungdong Pharmaceutical Co., Ltd.
Essential Hypertension
Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential Hypertension
The purpose of this study was to evaluate the dose-response relationships of azilsartan, once daily (QD) in participants with mild to moderate uncomplicated essential hypertension.
- Trial name
- NCT01289132
- Testing
- Azilsartan, Candesartan cilexetil
- Volunteers
- 926 people
- Sponsor
- Takeda
Hypertension
A Study to Evaluate the Efficacy and Safety of Quinapril or Quinapril Plus Hydrochlorothiazide in Patients With Mild to Moderate Hypertension
The purpose of this study is to determine the response rate for the therapeutic goal (diastolic blood pressure (BP) less than 90 mmHg and systolic BP less than 140 mmHg) at Week 6 for quinapril 20 mg and at Week 12 for quinapril…
- Trial name
- NCT00651287
- Testing
- quinapril 20 mg, quinapril 20 mg plus hydrochlorothiazide 12.5 mg, quinapril 40 mg
- Where
- 3 sites in Turkey (Türkiye)
- Volunteers
- 200 people
- Sponsor
- Pfizer
Essential Hypertension ( Mild to Moderate)
Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension
This study will assess the efficacy of an aliskiren based treatment regimen in reaching blood pressure (BP) target in patients with mild to moderate hypertension.
- Trial name
- NCT00765947
- Testing
- Aliskiren, Hydrochlorothiazide, Amlodipine
- Where
- 4 sites in France, Hungary and 2 more
- Volunteers
- 256 people
- Sponsor
- Novartis
Hypertension, Metabolic Disorder
A 52 Week Study to Evaluate the Effects of Losartan With or Without HCTZ on Plasma Glucose, Metabolic Parameters, Blood Pressure in Hypertensive Patients With Metabolic Syndrome (0954A-331)
To determine if a one year treatment Losartan with or without HCTZ at different dosages have an effect on metabolic parameters in patients with hypertension and the metabolic syndrome.
- Trial name
- NCT00546052
- Testing
- losartan potassium (+) hydrochlorothiazide
- Volunteers
- 1,738 people
- Sponsor
- Organon and Co
Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension, Interstitial Lung Disease
A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
This study evaluates the effect of ROC-101 in adults with either Pulmonary Arterial Hypertension (PAH) or Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD-PH).
- Trial name
- ROCSTAR (NCT07175038)
- Testing
- ROC-101
- Where
- 24 sites in United States, Australia and 7 more
- Volunteers
- 40 people
- Sponsor
- AllRock Bio, Inc.
Hypertension
An Observational Study to Investigate the Efficacy, Safety, Tolerability and the Effect on Quality of Life of Telmisartan (Micardis) and Telmisartan With HCTZ (Micardis Plus) in Patients With Hypertension
An observational study to investigate the efficacy, safety, tolerability and the effect on quality of life of Telmisartan (Micardis) and Telmisartan with HCTZ (Micardis Plus) in patients with hypertension
- Trial name
- NCT00904215
- Testing
- telmisartan/telmisartan + HCTZ (Hydrochlorothiazide)
- Where
- 11 sites in South Korea
- Volunteers
- 1,095 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.